Scienture Holdings, Inc.(SCNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SCNX Scienture Holdings, Inc.

Market Closed 01-16 16:00:00 EST

0.5300

+0.0073

+1.40%

盘后0.5144

-0.0156-2.94%

19:51 EST

High0.5334	Low0.5090	Vol612.35K
Open0.5144	D1 Closing0.5227	Amplitude4.67%
Mkt Cap21.53M	Tradable Cap18.02M	Total Shares40.63M
T/O318.30K	T/O Rate1.80%	Tradable Shares33.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SCNX","market":"US","secType":"STK","nameCN":"Scienture Holdings, Inc.","latestPrice":0.53,"timestamp":1768597200000,"preClose":0.5227,"halted":0,"volume":612351,"hourTrading":{"tag":"盘后","latestPrice":0.5144,"preClose":0.53,"latestTime":"19:51 EST","volume":8237,"amount":4261.2856,"timestamp":1768611071098},"delay":0,"floatShares":33992500,"shares":40630815,"eps":-1.7229,"marketStatus":"Market Closed","change":0.0073,"latestTime":"01-16 16:00:00 EST","open":0.5144,"high":0.5334,"low":0.509,"amount":318302.25426360004,"amplitude":0.046681,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.7229,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":0.5227,"preHourTrading":{"tag":"盘前","latestPrice":0.5075,"preClose":0.5227,"latestTime":"08:56 EST","volume":22138,"amount":11246.3774043,"timestamp":1768571808046},"postHourTrading":{"tag":"盘后","latestPrice":0.5144,"preClose":0.53,"latestTime":"19:51 EST","volume":8237,"amount":4261.2856,"timestamp":1768611071098},"volumeRatio":0.14922209988941212},"requestUrl":"/m/hq/s/SCNX/tweets","defaultTab":"tweets","newsList":[{"id":"2603619598","title":"BUZZ-Scienture Holdings jumps after U.S. FDA clears opioid overdose spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619598","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603619598?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:25","pubTimestamp":1768397155,"startTime":"0","endTime":"0","summary":"BUZZ-Scienture Holdings jumps after U.S. FDA clears opioid overdose spray** Shares of specialty pharma firm Scienture Holdings SCNX.O rise 19.99% to $0.6472 premarket** Co says U.S. FDA has approved a new high-dose nasal spray, Rezenopy, for treating opioid overdoses** Says spray delivers 10mg naloxone to reverse overdoses from powerful opioids including fentanyl** Adds SCNX holds exclusive U.S. sales rights; Summit Biosciences will manufacture the product** Patent protection runs through February 2041; naloxone market worth $154 million, with 9.3 million units sold annually - IQVIA data** As of last close, stock down ~92% over the past year","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nL4N3YF19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","LU0130517989.USD","LU1791710400.SGD","LU0882574055.USD","LU0477156953.USD","LU0477156797.USD","LU1261432733.SGD","LU0130102774.USD","SCNX","LU0130518102.USD","BK4121","LU0130103400.USD","LU1791710582.SGD","LU1989764748.USD","BK4530","BK4585","LU0198837287.USD","BK4588","LU1201861249.SGD","LU0648001328.SGD","LU0980610538.SGD","LU0648000940.SGD","LU1201861165.SGD","IQV","LU1989764664.SGD","LU0528227936.USD"],"gpt_icon":0},{"id":"2603616116","title":"Scienture Announces Issuance of Orange Book-Listable Patent Covering Rezenopy™, the Highest Dosage Naloxone Hcl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616116?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:05","pubTimestamp":1768395900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nTUA3JWGMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2603616558","title":"EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616558","media":"Benzinga_recent_news","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616558?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:51","pubTimestamp":1768395060,"startTime":"0","endTime":"0","summary":"New US patent strengthens protection for Rezenopy, the FDA-approved 10 mg naloxone nasal spray.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/14/Naloxone-And-Narcan-Nasal-Spray-In-The-E.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/14/Naloxone-And-Narcan-Nasal-Spray-In-The-E.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49901588/exclusive-penny-stock-scientures-partner-secures-us-patent-for-highest-dosage-naloxone-spray-for-emergency-opioid-overdose-treatment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/49901588/exclusive-penny-stock-scientures-partner-secures-us-patent-for-highest-dosage-naloxone-spray-for-emergency-opioid-overdose-treatment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2593348026","title":"BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy","url":"https://stock-news.laohu8.com/highlight/detail?id=2593348026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593348026?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:22","pubTimestamp":1766409727,"startTime":"0","endTime":"0","summary":"BRIEF-Scienture Provides Update On The Commercial Launch Of RezenopyDec 22 (Reuters) - Scienture Holdings Inc SCNX.O:SCIENTURE PROVIDES UPDATE ON THE COMMERCIAL LAUNCH OF REZENOPY, THE HIGHEST STRENGT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA1DGPVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2593803154","title":"Scienture Holdings Launches High-Strength REZENOPY Naloxone Nasal Spray in U.S. Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2593803154","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593803154?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:05","pubTimestamp":1766408730,"startTime":"0","endTime":"0","summary":"Scienture Holdings Inc. has announced an update on the commercial launch of REZENOPY, a high-strength 10 mg naloxone HCl nasal spray, following its FDA approval in April 2024. Through an exclusive agreement with Summit Biosciences Inc., Scienture will oversee the U.S. commercialization of REZENOPY. The company plans to load the product into wholesale channels in the first quarter of 2026, with commercial availability expected in early Q2 2026. This initiative marks a significant expansion in Scienture’s product portfolio, aiming to address the growing need for effective opioid overdose treatments in the U.S. market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the original content used to generate th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDLbp8Fnv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","SG9999014039.USD","BK4167","BK4585","IE00BKPKM429.USD","LU2095319765.USD","SCNX","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2593906480","title":"Scienture Holdings Inc - Rezenopy Expected Commercially Available Early Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2593906480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593906480?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:05","pubTimestamp":1766408700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA1DGPVY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2593480575","title":"SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2593480575","media":"GlobeNewswire","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593480575?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:05","pubTimestamp":1766408700,"startTime":"0","endTime":"0","summary":"U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec.  22, 2025  (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for exist","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/22/3209189/0/en/SCIENTURE-Provides-Update-on-the-Commercial-Launch-of-REZENOPY-the-Highest-Strength-Naloxone-HCl-Life-Saving-Opioid-Overdose-Emergency-Treatment-Approved-by-the-FDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2590713535","title":"Why Is Scienture Stock Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590713535","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590713535?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:53","pubTimestamp":1765378380,"startTime":"0","endTime":"0","summary":"Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/10/Scienture-Holdings--Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/10/Scienture-Holdings--Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49306538/why-is-scienture-stock-gaining-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49306538/why-is-scienture-stock-gaining-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2590587588","title":"BRIEF-SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand Patient Access To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan Potassium","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587588","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587588?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:06","pubTimestamp":1765371990,"startTime":"0","endTime":"0","summary":"BRIEF-SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand Patient Access To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan PotassiumDec 10 (Reuters) - Scienture Ho","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA1CKV4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2590587829","title":"Scienture and Blinkrx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587829","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587829?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:05","pubTimestamp":1765371900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA1CKV4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2590587580","title":"Scienture Holdings Inc - Arbli Expected on Blinkrx Platform in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587580?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:05","pubTimestamp":1765371900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA1CKV4T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2588530450","title":"SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588530450","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588530450?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680700,"startTime":"0","endTime":"0","summary":"COMMACK, NY, Dec.  02, 2025  (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced va","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197898/0/en/SCIENTURE-to-Participate-in-the-iAccess-Alpha-Virtual-Best-Ideas-Winter-Investment-Conference-2025-on-December-9-10-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2583059682","title":"Scienture Holdings Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583059682","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583059682?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:03","pubTimestamp":1763157803,"startTime":"0","endTime":"0","summary":"Scienture Holdings Inc. held its 2025 Annual Meeting of Stockholders on November 12, 2025. Stockholders voted on several key proposals, including the election of five directors to the board. Proposals also included the approval of a potential future offering of common stock that could result in the issuance of more than 20% of currently outstanding shares at a price below the minimum price, granting the board discretion to amend the charter to effect a reverse stock split at a ratio between one-for-two and one-for-fifty, and the approval of an adjournment of the meeting if necessary to solicit additional proxies. Each of these proposals was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL8rBtdX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2583443598","title":"Scienture reports Q3 EPS (19c) vs. ($1.34) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2583443598","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583443598?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:15","pubTimestamp":1763039724,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $590,050 vs. $64,861 last year. “Q3 was a transformational quarter for Scienture (SCNX) as we commenced sales of Arbli,” comment...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scienture-reports-q3-eps-19c-vs-1-34-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scienture-reports-q3-eps-19c-vs-1-34-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2583596155","title":"SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583596155","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583596155?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:05","pubTimestamp":1763039100,"startTime":"0","endTime":"0","summary":"Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertensi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187305/0/en/SCIENTURE-Reports-Q3-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","BK4167","SCNX"],"gpt_icon":0},{"id":"2583560663","title":"EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560663","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560663?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:50","pubTimestamp":1763038258,"startTime":"0","endTime":"0","summary":"Scienture&#39;s Q3 revenue surged on Arbli sales, debt dropped, and cash rose to $8 million ahead of its planned Rezenopy launch in early 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/25/11/48830985/exclusive-scienture-delivers-q3-revenue-jump-with-arbli-sales-and-debt-reduction","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2580973434","title":"Scienture Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2580973434","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580973434?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:05","pubTimestamp":1762261519,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG164:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCNX","BK4167"],"gpt_icon":0},{"id":"2580273105","title":"EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives","url":"https://stock-news.laohu8.com/highlight/detail?id=2580273105","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580273105?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:51","pubTimestamp":1762260660,"startTime":"0","endTime":"0","summary":"Scienture's Arbli losartan oral suspension gains access to over 100 million covered lives through national commercial and Medicare formularies.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/04/Pulmonary-Hypertension-Medicine-Doctor-H.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/04/Pulmonary-Hypertension-Medicine-Doctor-H.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/11/48617443/exclusive-scienture-expands-access-to-arbli-losartan-oral-suspension-with-addition-to-formularies-covering-100-million-lives","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48617443/exclusive-scienture-expands-access-to-arbli-losartan-oral-suspension-with-addition-to-formularies-covering-100-million-lives","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4167","SCNX"],"gpt_icon":0},{"id":"2577761538","title":"Crude Oil Surges 5%; American Airlines Shares Jump After Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2577761538","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577761538?lang=en_us&edition=fundamental","pubTime":"2025-10-24 03:23","pubTimestamp":1761247439,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/10/48390781/crude-oil-surges-5-american-airlines-shares-jump-after-q3-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4020","IE00B66KJ199.SGD","BK4585","TQQQ","PSQ","GTX","QLD","RBBN",".IXIC","BK4141","TSYW.SI","BK4588","BK4167","VTYX","IE00B7SZL793.SGD","USJW.SI","SCNX","BK4212","QID","BK4124","NQmain","MNQmain","LU2211817866.USD","USAW.SI","IE00BMPRXN33.USD","IE0031619046.USD","AAL","BK4007","NVIW.SI","BK4605","IE00B19Z4B17.USD","BK4554","BK4008","SQQQ","LU0006061336.USD","IE00BMPRXR70.SGD","BK4604","STM","BK4500","SMPL","BK4547"],"gpt_icon":1},{"id":"2577419587","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2577419587","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577419587?lang=en_us&edition=fundamental","pubTime":"2025-10-24 02:02","pubTimestamp":1761242579,"startTime":"0","endTime":"0","summary":"Scienture  reported Thursday the start of commercial sales and fulfillment of the first customer orders for an Arbli  oral suspension, 10 milligrams per milliliter.Shares more than doubled as intraday trading volume catapulted to over 575 million from a daily average of about 2.2 million.Ventyx Biosciences  shares soared 91% amid heavy trading after the company overnight said VTX3232 demonstrated significant reductions in cardiovascular risk factors in a trial in phase 2 in patients with obesity and cardiovascular risks.Intraday trading volume soared to over 103 million shares from a daily average of roughly 1.3 million.Garrett Motion  reported stronger-than-expected Q3 earnings and net sales and raised its cash dividend while adjusting full-year 2025 revenue guidance.Shares jumped 21%, with more than 4.9 million intraday trading volume compared with a daily average of about 3.2 million.Price: 1.35, Change: +0.77, Percent Change: +135.35","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4167","IE00B19Z4B17.USD","GTX","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4124","BK4007","IE0031619046.USD","VTYX","SCNX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.scienture.com","stockEarnings":[{"period":"1week","weight":-0.0537},{"period":"1month","weight":0.06},{"period":"3month","weight":-0.0095},{"period":"6month","weight":-0.7494},{"period":"1year","weight":-0.884},{"period":"ytd","weight":0.0392}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.094897},{"month":2,"riseRate":0.4,"avgChangeRate":0.191275},{"month":3,"riseRate":0.5,"avgChangeRate":-0.029282},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.139837},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.114903},{"month":6,"riseRate":1,"avgChangeRate":0.56391},{"month":7,"riseRate":0.666667,"avgChangeRate":0.096061},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.16799},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.047954},{"month":10,"riseRate":0,"avgChangeRate":-0.160548},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.067192},{"month":12,"riseRate":0,"avgChangeRate":-0.185859}],"exchange":"NASDAQ","name":"Scienture Holdings, Inc.","nameEN":"Scienture Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Scienture Holdings, Inc.(SCNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Scienture Holdings, Inc.(SCNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Scienture Holdings, Inc.,SCNX,Scienture Holdings, Inc.股票,Scienture Holdings, Inc.股票老虎,Scienture Holdings, Inc.股票老虎国际,Scienture Holdings, Inc.行情,Scienture Holdings, Inc.股票行情,Scienture Holdings, Inc.股价,Scienture Holdings, Inc.股市,Scienture Holdings, Inc.股票价格,Scienture Holdings, Inc.股票交易,Scienture Holdings, Inc.股票购买,Scienture Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Scienture Holdings, Inc.(SCNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Scienture Holdings, Inc.(SCNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction